Ravulizumab Treatment Outcomes in Patients With Generalized Myasthenia Gravis
ConditionMyasthenia Gravis, Generalized
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorAstraZeneca
About this trial
The Polish multicentre observational (non-interventional) study aiming to collect data on the management and clinical outcomes of patients with gMG that received ravulizumab.
Eligibility criteria
Qualifiers
Adult (aged ≥18 years) patients with gMG, naive to complement inhibitors, receiving ravulizumab treatment in the frames of NDP in Poland.
Patients willing to participate in the study and signed Informed Consent Form (ICF).
Vaccination against N. meningitidis
Disqualifiers
Those who plan to participate in gMG clinical trial on/after the date of first ravulizumab infusion through NDP.
Cognitive incapacity, unwillingness or language barriers precluding adequate understanding or cooperation.
Trial design
Treatments tested in this trial
- Ravulizumab
Treatment groups
50 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov